Session Details
[S04☆]Current status and future challenges of the revised cannabis control act
Fri. Mar 27, 2026 9:30 AM - 11:30 AM JST
Fri. Mar 27, 2026 12:30 AM - 2:30 AM UTC
Fri. Mar 27, 2026 12:30 AM - 2:30 AM UTC
Room 08 (A501, Bldg. 1, Area 2 [5F])
Organizer: Masahiko Funada (Fac. Pharmaceut. Sci., Shonan Univ. of Medical Sciences), Ruri Kikura-Hanajiri (National Inst. Health Sciences)
Cannabis abuse is on the rise both domestically and internationally, with the problem of cannabis abuse among young people becoming increasingly prominent in Japan. Meanwhile, regarding medical applications of cannabis, pharmaceuticals utilizing cannabis components, such as Epidiolex (cannabidiol) for suppressing epileptic seizures, have been put into practical use, and medical demand is growing. However, under the previous Cannabis Control Act, the use of cannabis-derived pharmaceuticals was generally prohibited, making appropriate legal revision necessary. In response to this situation, Japan amended the Cannabis Control Act (promulgated December 2023). The key points of this amendment are fourfold: (1) Addressing the medical need for cannabis-derived pharmaceuticals, (2) Establishing a new offense for cannabis use, (3) Regulating THC concentration in products, and (4) Reviewing regulations on cannabis plant cultivation and management. Going forward, sales of cannabis-related products are expected to grow further. To ensure the safe and secure use of these products, establishing a consistent system covering everything from cannabis cultivation to product safety management is desirable. This symposium will organize the domestic and international background leading to the Cannabis Control Act revision, its outline, and current challenges, and will examine the future direction of regulations for cannabis and cannabis-derived products.
[S04-1]Background and current status of the cannabis control law revision
○Masahiko FunaFunada1 (1. Faculty of Pharmaceutical Sciences, Shonan University of Medical Sciences)
[S04-2]Global trends in cannabis regulation and therapeutic use: Current status and challenges with a focus on the United States
○Kenichi Tomiyama1, Masahiko Funada1,2 (1. National Center of Neurology and Psychiatry, 2. Faculty of Pharmaceutical Sciences, Shonan University of Medical Sciences)
[S04-3]Distribution of products containing THC analogs and their related compounds in Japan
○Ruri Kikura-Hanajiri1, Rie Tanaka1 (1. National Institute of Health Sciences)
[S04-4]Cannabinoid detection in edible products containing cannabis-related ingredients
○Noriyuki Usami1, Asuka Moribayashi1, Rina Kato1, Kai Arugai1, Ayako Kitano1, Takuya Shuo2 (1. Faculty of Pharmaceutical Sciences, Hokuriku Univ., 2. Faculty of International Communication, Hokuriku Univ.)
[S04-5]Medical applications of cannabidiol and cytotoxicity evaluation
○Koshiro Sogawa1, Ryuichiro Hosoya1, Daigo Ikegami1, Hideaki Kato1, Masahiko Funada1 (1. Faculty of Pharmaceutical Sciences, Shonan University of Medical Sciences)
[S04-6]Research contributing to the development of management standards for Industrial cannabis cultivation
○Hiroyuki Fuchino1,2, Noriaki Kawano2, Takayuki Inui2, Kayo Yoshimatsu2 (1. Niigata University of Pharmacy and Medical and Life Sciences, 2. National Institutes of Biomedical Innovation, Health and Nutrition)